ViAqua Therapeutics Overview
ViAqua Therapeutics is the developer of an orally administered treatment designed to improve health management and prevent viral epidemics in aquaculture. The company's first product is designed for use in shrimp, which comprises 20% of the total international trade value of fish products. ViAqua's platform for health management in shellfish and fish utilizes a proprietary RNAi formulation that triggers the immune system and prevents viral infections. The coated particles are delivered via feed to produce the maximum effect and reduce cost.
Cumulative Funding Raised Over Time ($)
$2.5MJul 2018
$6.8MJun 2021
$7.8MSep 2014
$16.1MSep 2023
Latest News
growth-positive
ViAqua Therapeutics Raises $8.25M in Funding
ViAqua Therapeutics, a biotechnology company based in Haifa, Israel, has raised $8.25M in funding. The round was led by S2G Ventures and included participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels, and Circle Investments LLC. The company plans to use the funds to bring its first product to market, invest in R&D for future products, and prove the platform’s ability to deliver RNA-based solutions at scale. ViAqua has also established a commercial partnership with Skretting, a Nutreco company, to bring the product to the market.
InvestmentPartners
growth-positive
ViAqua Therapeutics Announces $4.3 Million Investment led by S2G Ventures for its RNA-based Aquaculture Health Platform
ViAqua Therapeutics, an Israeli biotech developing an orally administered RNA-particle platform to improve animal health in aquaculture, completed a $4.3 million financing round to commercialize and scale its platform. New and returning investors include S2G Ventures, Thai Union, Agriline, Nutreco, VisVires New Protein, The Trendlines Group and the Technion, plus additional grant funding from the Israeli Innovation Authority. ViAqua’s proprietary production and encapsulation delivery approach targets viral diseases in shrimp—where outbreaks can cause near-total mortality—and aims to reduce the significant global losses from disease. The company plans to scale up production, expand its product pipeline, and pursue commercialization to address aquatic disease challenges while minimizing environmental impact.
Product StageInvestmentPartnersExpand
https://www.businesstimes.com.sg/technology/sg-fund-visvires-new-protein-invests-in-israeli-shrimp-virus-tech-startup-viaqua
growth-positive
Israeli startup silences diseased genes of shrimp to boost their production
Israeli biotechnology startup ViAqua Therapeutics has developed a feeding solution using RNA molecules to inhibit gene expression and neutralize viral infections in shrimp and other aquaculture species. The company received an investment from Nutreco Investments BV and signed a collaboration agreement with Nutrecos aquaculture division, Skretting AS. The funding will support the development of ViAquas first product and help meet registration requirements. The partnership with Nutreco provides an opportunity for ViAqua to develop technologies tailored to the market. Disease prevention, particularly viral infections, is a major challenge in the aquaculture industry.
PartnersInvestment
growth-positive
Dutch Animal Feed Company Nutreco Invests in Medical Aquafarming Startup ViAqua
Dutch animal feed company Nutreco NV has led a funding round in ViAqua Therapeutics, a medical aquafarming startup. ViAqua also signed a joint development and marketing deal with Nutrecos aquafarming subsidiary Skretting AS. The funding will be used to complete the development and testing of ViAquas particle-based matrix for delivering antiviral medication to shrimp.
Partners
| Sector | Agriculture & Food Technologies |
Funding
| Total funding | $16.05M |
| Last funding | $8.25M |
| Stage | Seed |
| Rounds | 5 |
| Investors | 11 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.viaqua-t.com |
| Careers | Careers page |
Locations
Kadima Tzoran, Israel
Haifa, Israel
Photos & Videos
No files yet
ViAqua Therapeutics Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Climate TechFood & Land UseSustainable FarmingHealth Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryAgriculture & Food TechnologiesAg TechFarm Equipment & TreatmentTarget Customer
Agriculture & FoodMarine LifeFishSea FoodCore Technology
BiologicalsTags (10)
therapeuticsviral-diseasesfish-farmsagtechaquacultureclimate-techdrug-deliveryfarmersagriculturedisease-managementGeographic Markets
AsiaSouth AmericaAustraliaViAqua Therapeutics Financials
$16.05M
Total funding
Undisclosed
Capital raised
$8.25M
Last funding
Seed
Funding stage
5
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$2.5MJul 2018
$6.8MJun 2021
$7.8MSep 2014
$16.1MSep 2023
Private Equity Funding
Undisclosed Round
Sep 2023
$8.25M
S2G Investments (Lead)
,
I-Lab Angels, Circle Investments, Agriline, Nutreco, Rabobank, The Trendlines Group
Undisclosed Round
Jun 2021
$4.3M
S2G Investments, Thai Union Group, Clay Capital, Technion, Agriline, Nutreco, The Trendlines Group
Undisclosed Round
Jul 2018
$2.5M
Clay Capital, Nutreco
Seed
Sep 2014
$1M
Office of the Chief Scientist, The Trendlines Group
Non-Equity Funding
GrantEvent
Undisclosed
ViAqua Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$2.5MJul 2018
$6.8MJun 2021
$7.8MSep 2014
$16.1MSep 2023
All Events
Undisclosed Round
Sep 2023
$8.25M
S2G Investments (Lead)
,
I-Lab Angels, Circle Investments, Agriline, Nutreco, Rabobank, The Trendlines Group
Undisclosed Round
Jun 2021
$4.3M
S2G Investments, Thai Union Group, Clay Capital, Technion, Agriline, Nutreco, The Trendlines Group
Undisclosed Round
Jul 2018
$2.5M
Clay Capital, Nutreco
Seed
Sep 2014
$1M
Office of the Chief Scientist, The Trendlines Group
GrantEvent
Undisclosed
ViAqua Therapeutics News
5 articles
growth-positive
ViAqua Therapeutics Raises $8.25M in Funding
ViAqua Therapeutics, a biotechnology company based in Haifa, Israel, has raised $8.25M in funding. The round was led by S2G Ventures and included participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels, and Circle Investments LLC. The company plans to use the funds to bring its first product to market, invest in R&D for future products, and prove the platform’s ability to deliver RNA-based solutions at scale. ViAqua has also established a commercial partnership with Skretting, a Nutreco company, to bring the product to the market.
InvestmentPartners
growth-positive
ViAqua Therapeutics Announces $4.3 Million Investment led by S2G Ventures for its RNA-based Aquaculture Health Platform
ViAqua Therapeutics, an Israeli biotech developing an orally administered RNA-particle platform to improve animal health in aquaculture, completed a $4.3 million financing round to commercialize and scale its platform. New and returning investors include S2G Ventures, Thai Union, Agriline, Nutreco, VisVires New Protein, The Trendlines Group and the Technion, plus additional grant funding from the Israeli Innovation Authority. ViAqua’s proprietary production and encapsulation delivery approach targets viral diseases in shrimp—where outbreaks can cause near-total mortality—and aims to reduce the significant global losses from disease. The company plans to scale up production, expand its product pipeline, and pursue commercialization to address aquatic disease challenges while minimizing environmental impact.
Product StageInvestmentPartnersExpand
https://www.businesstimes.com.sg/technology/sg-fund-visvires-new-protein-invests-in-israeli-shrimp-virus-tech-startup-viaqua
growth-positive
Israeli startup silences diseased genes of shrimp to boost their production
Israeli biotechnology startup ViAqua Therapeutics has developed a feeding solution using RNA molecules to inhibit gene expression and neutralize viral infections in shrimp and other aquaculture species. The company received an investment from Nutreco Investments BV and signed a collaboration agreement with Nutrecos aquaculture division, Skretting AS. The funding will support the development of ViAquas first product and help meet registration requirements. The partnership with Nutreco provides an opportunity for ViAqua to develop technologies tailored to the market. Disease prevention, particularly viral infections, is a major challenge in the aquaculture industry.
PartnersInvestment
growth-positive
Dutch Animal Feed Company Nutreco Invests in Medical Aquafarming Startup ViAqua
Dutch animal feed company Nutreco NV has led a funding round in ViAqua Therapeutics, a medical aquafarming startup. ViAqua also signed a joint development and marketing deal with Nutrecos aquafarming subsidiary Skretting AS. The funding will be used to complete the development and testing of ViAquas particle-based matrix for delivering antiviral medication to shrimp.
Partners
ViAqua Therapeutics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 13 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
ViAqua Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515130250 |
| Crunchbase | viaqua-therapeutics |
| Last updater | Ortal Wein |
| Updater email | ortalw@sncentral.org |
| Last update | 2024-11-13T00:00:00.000Z |
| Created | 2015-04-26T00:00:00.000Z |
| Claimed | Yes |